Suven Pharma - Strong Overall Results Led By Pharma CRAMS: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Suven Pharmaceuticals Ltd.’s Q3 FY21 revenue grew 53.8% YoY to Rs 275 crore amid 1.75 times growth in pharma contract research and manufacturing services division sales to Rs 217 crore.
However, specialty chemical CRAMS nearly halved to Rs 35 crore whereas formulation sales fell 30% to Rs 23 crore.
More importantly, Ebitda margin was at 50.2% (up 568 basis points YoY) in Q3 on the back of better operational leverage, favourable product mix.
Hence, Ebitda grew 73.5% to Rs 138 crore. Profit after tax nearly doubled YoY to Rs 114 crore.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.